Quinapril — Discount Pricing

Other medications in Heart & Cardiovascular

• Ramipril
• Ranolazine
• Riociguat
• Rivaroxaban
• Rosuvastatin
• Sacubitril-Valsartan
• Selexipag
• Sildenafil (PAH)

What Quinapril is approved for (FDA label)

Hypertension Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.

Source: Read the full FDA label on DailyMed. Label effective date: January 1, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Quinapril (FDA label)

WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue quinapril tablets as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS : Fetal Toxicity

Source: FDA prescribing information (DailyMed). Set ID: da562e3b-4411-e750-e053-2a95a90ad7e5. SPL document ID: 49514d2d-e05b-44ba-e063-6394a90ad56a. Label effective date: January 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Quinapril (FDA label)

Hypertension Quinapril has been evaluated for safety in 4960 subjects and patients. Of these, 3203 patients, including 655 elderly patients, participated in controlled clinical trials. Quinapril has been evaluated for long-term safety in over 1400 patients treated for 1 year or more. Adverse experiences were usually mild and transient. In placebo-controlled trials, discontinuation of therapy because of adverse events was required in 4.7% of patients with hypertension. Adverse experiences probably or possibly related to therapy or of unknown relationship to therapy occurring in 1% or more of the 1563 patients in placebo-controlled hypertension trials who were treated with quinapril are shown below.

Source: FDA prescribing information (DailyMed). Set ID: da562e3b-4411-e750-e053-2a95a90ad7e5. SPL document ID: 49514d2d-e05b-44ba-e063-6394a90ad56a. Label effective date: January 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Quinapril (FDA label)

Quinapril is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Quinapril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer quinapril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS and PRECAUTIONS ). Do not co-administer quinapril with aliskiren in patients with diabetes.

Source: FDA prescribing information (DailyMed). Set ID: da562e3b-4411-e750-e053-2a95a90ad7e5. SPL document ID: 49514d2d-e05b-44ba-e063-6394a90ad56a. Label effective date: January 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.